Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Vaccine. 2010 Jul 12;28(31):5023-30. doi: 10.1016/j.vaccine.2010.05.014. Epub 2010 May 21.

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.

Author information

  • 1Novartis Vaccines and Diagnostics, Via Fiorentina 1, Siena 53100, Italy.

Abstract

Serum bactericidal activity using human complement is the basis for established correlates of protection against invasive meningococcal disease. During the development of multicomponent protein-based vaccines against meningococcus B, it is necessary to measure antigen-specific bactericidal responses. This is not straightforward because each strain may be killed by antibodies to multiple antigens. We characterized a large panel of strains and, using a competitive inhibition SBA, we identified four strains that are each specifically killed by bactericidal antibodies to one of the major vaccine components. These strains provide a straightforward approach to demonstrate protective responses to each component of the vaccine and demonstrate that each of the antigens in the vaccine is sufficient to provide a potentially protective level of bactericidal activity.

Copyright 2010 Elsevier Ltd. All rights reserved.

PMID:
20493284
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk